Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome

Immune checkpoint blockade (ICPB) is a powerfully effective cancer therapy in some patients. Tumor neo-antigens are likely main targets for attack but it is not clear which and how many tumor mutations in individual cancers are actually antigenic, with or without ICPB therapy and their role as neo-a...

Full description

Bibliographic Details
Main Authors: Shaokang Ma, Jonathan Chee, Vanessa S. Fear, Catherine A. Forbes, Louis Boon, Ian M. Dick, Bruce W. S. Robinson, Jenette Creaney
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
neo-antigen
checkpoint blockade
t cells
mesothelioma
biomarker
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1684714

Internet

http://dx.doi.org/10.1080/2162402X.2019.1684714

Similar Items